Spending on television advertising might be on the rise, but the consumer ad spend for prescription drugs is seeing a downward trend.

Things heat up in Washington as FDA is called to task for a controversial contracts deal with a local public relations firm. Both the Senate and the House are looking for answers, and the feds no longer have a PR firm to run damage control.

Once a breeding ground for dense jargon about mechanisms of action and prescribing information, Web sites like Centocor's new Medversation are giving doctors consumer-friendly content to help them spell out treatment options in a language everyone can understand.

Significant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole?

Once considered the future of weight loss drugs, CB-1 antagonists have now been shelved globally. With failures from Pfizer, Merck, and Sanofi-Aventis, analysts say that this is the end of a potential blockbuster therapy.

AstraZeneca caused a ruckus at the American Heart Association's annual meeting as data was released proving that its statin not only works for its target indication, but also reduced major CV events in patients who don?t have high cholesterol.

US heparin manufacturer ordered to turn over contaminated batches of heparin. Just how much of the tainted chemical is on the market?

The global pharma market is expected to grow about 5 percent in 2009. The Winners: emerging markets and specialty drugs. The losers: the United States market and primary care drugs.

Colorful and cheerful aren’t always a good thing; an illustrated brochure for Amgen’s Sensipar gets canned by FDA for too thin a listing of side effects and adverse reaction data.